kambach

$JNJ will bounce - Dip opportunity

做多
NYSE:JNJ   Johnson & Johnson
I love JNJ long and believe that they are going to be fine with the recent COVID-related dip.

Their vaccine could do more damage than AstraZeneca's and governments will still buy it in order to herd the sheep.

You need to understand that JNJ is so much more than a vaccine company.

Expect this stock to go back up to the $167 level, as well as breaking the $170 level as well.

A great swing trade (buy covid dips), and I also love this long-term.

Lots of money to be made here!


*Not a financial advisor.

**Don't judge me on my winners. Judge me on my losers, because there are so few.
免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。